Featured Research

from universities, journals, and other organizations

Molecular, protein targeting therapies may be best treatment for certain lung cancer

Date:
January 7, 2014
Source:
University of Cincinnati Academic Health Center
Summary:
Researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with the condition.

University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with the condition.

These findings are being presented via poster at the American Association for Cancer Research- International Association for the Study of Lung Cancer Joint Conference on the Molecular Origins of Lung Cancer, Jan. 6-9, 2014, in San Diego.

Non-small-cell lung cancer is any type of lung cancer other than small-cell lung cancer -- the most common type of lung cancer. Non-small-cell lung cancer with KRas mutation is non-druggable, and no successful targeted therapy currently exists to help patients with this form of lung cancer.

Nagla Karim, MD, PhD, a member of the institute, assistant professor in the division of hematology oncology at the UC College of Medicine, UC Health physician and principal investigator on this study, says researchers assessed the molecular profiling and sensitivity to the KRas mutant lung cancer in comparison with the wild type, or non-mutant, lung cancer.

"Recent studies suggest that patients with KRas-mutant non-small-cell lung cancer do not often benefit from standard systemic therapies and do not respond to epidermal growth factor receptor inhibitors, which are used to control the progression of cancer," she says.

"There is a need for therapies specifically developed for these patients, and molecular profiling has the potential to identify possible targets that might provide better treatment and innovative targeted therapy for KRas-mutated non-small-cell lung cancer."

The mutation of a KRas gene is an essential step in the development of many cancers, including non-small-cell lung cancer.

In the study, researchers purified RNA from banked tumor and normal lung tissue obtained from 20 patients with wild-type and 17 patients with mutant-type KRas non-small-lung cancer tumors which were being removed in stages I and II.

"We assessed the expression of four genes involved in cell synthesis and repair, and our results show that in mutant-type KRas tumors, the levels of expression of several of three of the genes (BRCA1, TS and SRC) were significantly increased in comparison to normal lung tissue," Karim says. "The expression of the same genes was significantly increased in wild-type KRas tumors relative to their expression in normal lung.

"Interestingly, SRC expression in mutant-type KRas tumors was decreased in comparison to wild-type KRas tumors. These findings suggest that greater expression of the gene ERCC1 in mutant KRas tumors might increase platinum-based chemotherapy resistance in this group of patients, whereas the greater expression of the BRCA1 in wild KRas tumors might suggest sensitivity to taxanes, which are chemotherapy agents."

She adds that this data also suggests that the combination of an approved SRC inhibitor with a TS inhibitor might improve the outcome of patients with wild-type KRas tumors.

"These results shed new light on potentially more effective treatment strategies for patients with various types of KRas-related non-small-cell lung cancer," she says. "We hope that these findings will lead to better therapies and improved outcomes for patients."


Story Source:

The above story is based on materials provided by University of Cincinnati Academic Health Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Cincinnati Academic Health Center. "Molecular, protein targeting therapies may be best treatment for certain lung cancer." ScienceDaily. ScienceDaily, 7 January 2014. <www.sciencedaily.com/releases/2014/01/140107170731.htm>.
University of Cincinnati Academic Health Center. (2014, January 7). Molecular, protein targeting therapies may be best treatment for certain lung cancer. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2014/01/140107170731.htm
University of Cincinnati Academic Health Center. "Molecular, protein targeting therapies may be best treatment for certain lung cancer." ScienceDaily. www.sciencedaily.com/releases/2014/01/140107170731.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins